ATOPIC DERMATITIS (AD)

This study looks at the long-term safety and effectiveness of a drug called CM512 for people with atopic dermatitis (eczema). It is for patients who already finished treatment in an earlier CM512 study. The main goal is to track any side effects over time.

This early-stage study tests a new oral drug, LPX-TI641, in 48 adults with atopic dermatitis (eczema) or psoriasis. The main goal is to check if the drug is safe and tolerable compared to a placebo over 28 days. Researchers will also measure how the drug moves through the body. T…

This study looks at whether using CeraVe emollient can keep the skin barrier hydrated and prevent eczema from coming back after a short course of steroid cream. About 98 adults with mild-to-moderate atopic dermatitis will first use a steroid to clear their rash, then be split int…

This study is testing whether a partially hydrolyzed formula with added synbiotics can prevent atopic dermatitis (eczema) in 400 infants who are at risk for allergies. The babies will be enrolled within the first two weeks of life and followed to see if the formula helps maintain…

This study tests an experimental drug called BFB759 for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with standard creams. About 225 participants will receive either BFB759 or a placebo for up to 40 weeks. Researchers will track changes in skin r…

This early-stage study tests a new drug called ATTO-3712 in healthy adults and people with atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo and will be monitored through…

This study tests an over-the-counter drug for atopic dermatitis (eczema) in 36 adults with active flare-ups. Researchers will check how the drug affects skin bacteria, hydration, and barrier function. The goal is to see if the product can ease symptoms and improve skin health.

This early-stage study tests whether a new medicine called ZL-1503 is safe for people with moderate to severe atopic dermatitis (eczema). About 84 healthy volunteers and eczema patients will receive either the drug or a placebo. Researchers will monitor for side effects and how t…

This study tests a new daily pill, ENV-294, in 60 adults with moderate-to-severe eczema (atopic dermatitis) who haven't had success with creams. For 12 weeks, participants take either the drug or a placebo and visit the clinic regularly to track skin improvement and any side effe…

This early-stage study tests a new drug called ARQ-234 for people with moderate to severe atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. The study includes healthy volunteers and people with eczema, who will receive either…

This study tests whether a cream made with glycomacropeptide (a milk protein) can reduce itching, redness, and skin bacteria in children aged 2 to 12 with mild eczema. About 20 kids will apply either the special cream or a regular moisturizer twice a day for 4 weeks. Researchers …

This early-stage study compares a new drug, GS101, to the approved treatment Dupixent® for atopic dermatitis (eczema). It involves 294 healthy adult volunteers in China to see how the body processes each drug, their safety, and any immune reactions. The goal is to check if GS101 …

This study examines whether newborns with a family history of allergies have self-reactive antibodies in their cord blood that may predict eczema. Researchers will follow 500 babies for two years, checking their skin and antibody levels at birth, 6, 12, and 24 months. The goal is…

This study looks at how the skin of people with moderate-to-severe eczema changes when they are treated with tralokinumab. Researchers will use a special, non-invasive microscope to see the skin's structure in detail. The goal is to better understand how the treatment works on a …

This early-stage study looks at how nerves and immune cells talk to each other in the skin of people with mild-to-moderate eczema. Researchers will give a small number of participants botulinum toxin (Botox) injections to see how it changes these interactions. The goal is to lear…